OptiBiotix Health PLC’s (LON:OPTI) Stephen O'Hara speaks to Proactive London's Andrew Scott soon after the news its LPLDL probiotic had been granted ‘generally recognised as safe’ (GRAS) status by the US Food and Drug Administration (FDA).
Its subsidiary, ProBiotix Health Ltd, received the GRAS after completing process validation under pharmaceutical good manufacturing practices (GMP), which test whether a drug substance such as LPLDL is produced consistently at pharmaceutical grade quality.